Skip to main content
Caplight Logo









MucoLife Therapeutics

MucoLife Therapeutics

Private
GothenburgHealthcare & Life Scienceshttps://mucolife.com/

Last Round

Accelerator

Sep 6, 2024

Total Funding Raised

$30,000

Company Overview

MucoLife Therapeutics is a biotechnology company developing inhaled therapies for pulmonary mucus obstruction in chronic lung diseases such as COPD and cystic fibrosis.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

inhaled mucolyticmuco-obstructive lung diseaseCOPDcystic fibrosisfirst-in-class therapyrespiratory therapeuticsCFchronic obstructive pulmonary diseasepreclinical biotechairway clearancedrug developmentmucin biologypharma licensingnebulizer deliveryuniversity spin-outbronchiectasisasthma

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

MucoLife Therapeutics Comparables

Compare MucoLife Therapeutics with similar companies based on industry and business-model similarity.

MucoLife Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
CILA Therapeutics
88%
Aer Therapeutics
79%
Synedgen, Inc.
79%

MucoLife Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
AcceleratorSep 6, 2024

Key People

Founding team and executive leadership

Thaher Pelaseyed

Chief Executive Officer

Executive Team

MucoLife Therapeutics Investors

Notable investors and investment history

MucoLife Therapeutics investors
InvestorRounds
Vasa Angels IAccelerator

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 6, 2024

    $30K round led by Health Wildcatters

MucoLife Therapeutics Filings

Explore SEC and related filing metadata, where available.

MucoLife Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about MucoLife Therapeutics's valuation, stock price, and market status.

Is MucoLife Therapeutics a public or private company?

MucoLife Therapeutics is a private company.

What is the current stock price of MucoLife Therapeutics?

MucoLife Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is MucoLife Therapeutics worth (valuation)?

Valuation information for MucoLife Therapeutics is not publicly available.

Can I buy MucoLife Therapeutics stock?

MucoLife Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was MucoLife Therapeutics's last funding round?

MucoLife Therapeutics's most recent funding round was Accelerator on September 6, 2024.

Who are the main investors in MucoLife Therapeutics?

Key investors in MucoLife Therapeutics include Vasa Angels I.

Will MucoLife Therapeutics IPO soon?

No public IPO plans have been announced for MucoLife Therapeutics.

How can I track MucoLife Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor MucoLife Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersGothenburg
Employee Range1
Year Founded2023
Last FundingSep 6, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?